ISPOR Plenary: US Pharmaceutical Policy: Leading or Following?

Dana Goldman, PhD, Co-Founder and Scientific Advisor of EntityRisk and Director of the USC Schaeffer Center, will moderate the plenary to discuss the economic, regulatory, and long-term consequences of U.S. pharmaceutical policies in both the US and abroad.

Upcoming: Let's meet in Philadelphia!

Join EntityRisk and industry leaders for a discussion on how HEOR and Market Access professionals are navigating the evolving policy, access, and value landscapes.

Come visit us at Booth #805.

About EntityRisk

EntityRisk integrates globally renowned health economics and policy expertise with PROVEN™, our advanced modelling software, to predict health outcomes, identify maximum value-based pricing, and substantiate evidence-generation investments.

10 of the Top 20 Biopharma Companies work with EntityRisk to navigate the shifting policy landscape and confidently choose and defend justifiable prices, inform evidence investments, and communicate and win on value.

10 / 20

Top Biopharma Companies

1,300+

Quality Checks

5

ML Modules

Leverage software built by a team with world- class scientific, engineering and industry credentials.